- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nuvalent Inc (NUVL)
Track today's live Nuvalent (NUVL) share price, performance and key data on this page with our current NASDAQ:NUVL stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Nuvalent share price on the NASDAQ exchange. Use the dropdown to switch exchange for the NUVL share price, head to our technical summary section, which provides analysis on Nuvalent share price buy/sell indicators using real-time data (or discuss the Nuvalent (NUVL) stock price today with other investors in the Nuvalent NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:NUVL share price (ISIN: US6707031075) to enhance your trading decisions with our free investment tools and resources.
What Is the Nuvalent Inc Share Price Today?
The Nuvalent share price today is 123.52.
What Is the Stock Symbol for Nuvalent Inc
The stock symbol (or 'ticker') for Nuvalent Inc is "NUVL."
What Stock Exchange Does Nuvalent Inc Trade On?
Nuvalent Inc is listed and trades on the NASDAQ stock exchange.
Is Nuvalent Inc a Good Stock to Buy?
Determining whether Nuvalent (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:NUVL share price (ISIN: US6707031075) to enhance your trading decisions with our free investment tools and resources.
What Is the Nuvalent Inc Share Price Today?
The Nuvalent share price today is 123.52.
What Is the Stock Symbol for Nuvalent Inc
The stock symbol (or 'ticker') for Nuvalent Inc is "NUVL."
What Stock Exchange Does Nuvalent Inc Trade On?
Nuvalent Inc is listed and trades on the NASDAQ stock exchange.
Is Nuvalent Inc a Good Stock to Buy?
Determining whether Nuvalent (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
123.45
123.69
52 wk Range
71.13
123.69
Trading near 52-week High
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
123.45123.69
52 wk Range
71.13123.69
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NUVL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
125.13
Upside
+1.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Nuvalent receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Nuvalent receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 4 Nuvalent Inc For: 18 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
0 Buy
17 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 125.13
(+1.30% Upside)
Nuvalent Inc SWOT Analysis
Pipeline Progress | Explore Nuvalent's advancing oncology pipeline, with zidesamtinib and neladalkib showing promise in ROS1 and ALK-positive NSCLC clinical trials |
Market Potential | Delve into Nuvalent's strategy to capture both treatment-experienced and first-line markets, potentially positioning it as a leader in targeted therapies |
Financial Outlook | Analysts maintain a positive stance with a $100 price target, despite current unprofitability. EPS projections for FY2025 stand at -$5.07 |
Competitive Edge | Learn how Nuvalent's focus on improved safety profiles and efficacy could differentiate its therapies in the crowded oncology landscape |
Earnings
Latest Release
07/05/2026
EPS / Forecast
-1.39 / -1.35
Revenue / Forecast
-- / --
Compare NUVL to Peers and Sector
Metrics to compare | NUVL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.7x | −6.0x | −0.4x | |
PEG Ratio | 0.58 | 0.02 | 0.00 | |
Price/Book | 8.3x | 3.7x | 2.6x | |
Price / LTM Sales | - | 97.9x | 3.0x | |
Upside (Analyst Target) | 0.4% | 101.1% | 56.9% | |
Fair Value Upside | Unlock | −5.0% | 9.2% | Unlock |
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Nuvalent (NASDAQ: NUVL) Share Price Today?
The Nuvalent stock price today is 123.52 USD.
What Stock Exchange Does Nuvalent (NUVL) Trade On?
Nuvalent is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Nuvalent?
The stock symbol (also called a 'ticker') for Nuvalent is "NUVL."
What Is the Current Nuvalent Market Capitalisation?
As of today, Nuvalent (NASDAQ: NUVL) market cap is 9.76B USD.
What Is Nuvalent's (NUVL) Earnings Per Share (TTM)?
The Nuvalent EPS is currently -6.05 (Trailing Twelve Months).
When Is the Next Nuvalent Earnings Date?
Nuvalent's next earnings report will be released on 06/08/2026.
Is NUVL a Buy or Sell From a Technical Analyst Perspective?
Based on today's Nuvalent moving averages and other technical indicators, the daily buy/sell signal for NUVL stock is Strong Buy.
How Many Times Has Nuvalent Stock Split?
Nuvalent has split 0 times. (See the NUVL stock split history page for full effective split date and price information.)
How Many Employees Does Nuvalent Have?
Nuvalent has 234 employees, based on their latest Companies House report.
What is the current trading status of Nuvalent (NASDAQ: NUVL)?
As of 28/06/2026, Nuvalent (NUVL) is trading at a share price of 123.52 USD, with a previous close of 123.53 USD. The stock has fluctuated within a day range of 123.45 USD to 123.69 USD, while its 52-week range spans from 71.13 USD to 123.69 USD.
What Is Nuvalent (NUVL) Price Target According to Analysts?
The average 12-month price target for Nuvalent is 125.13 USD, with a high estimate of 140 USD and a low estimate of 124 USD. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +1.30% Upside potential.
What Is the NUVL Premarket Price?
NUVL's last pre-market stock price is 123.54 USD. The pre-market share volume is 6,250.00, and the stock has decreased by 0.01, or 0.01%.
What Is the NUVL After Hours Price?
NUVL's last after hours stock price is 123.75 USD, the stock has decreased by 0.23, or 0.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.